BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8523873)

  • 1. Influence of Duraflo II heparin-treated extracorporeal circuits on the systemic inflammatory response in patients having coronary bypass.
    Weerwind PW; Maessen JG; van Tits LJ; Stad RK; Fransen EJ; de Jong DS; Penn OC
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1633-41. PubMed ID: 8523873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass.
    Gu YJ; van Oeveren W; Akkerman C; Boonstra PW; Huyzen RJ; Wildevuur CR
    Ann Thorac Surg; 1993 Apr; 55(4):917-22. PubMed ID: 8466349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
    Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
    Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release of lipopolysaccharide toxicity-modulating proteins in patients undergoing cardiopulmonary bypass using noncoated and heparin-coated extracorporeal circuits. A clinical pilot study.
    Bouma M; Maessen J; Weerwind P; Dentener M; Fransen E; de Jong D; Buurman W
    Chest; 1997 Mar; 111(3):577-83. PubMed ID: 9118690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory response to cardiopulmonary bypass using two different types of heparin-coated extracorporeal circuits.
    Baufreton C; Moczar M; Intrator L; Jansen PG; te Velthuis H; Le Besnerais P; Farcet JP; Wildevuur CR; Loisance DY
    Perfusion; 1998 Nov; 13(6):419-27. PubMed ID: 9881389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits.
    Aldea GS; Soltow LO; Chandler WL; Triggs CM; Vocelka CR; Crockett GI; Shin YT; Curtis WE; Verrier ED
    J Thorac Cardiovasc Surg; 2002 Apr; 123(4):742-55. PubMed ID: 11986603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass.
    Yamada H; Kudoh I; Hirose Y; Toyoshima M; Abe H; Kurahashi K
    Acta Anaesthesiol Scand; 1996 Mar; 40(3):311-7. PubMed ID: 8721461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
    Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
    Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.
    Gunaydin S; McCusker K; Sari T; Onur MA; Zorlutuna Y
    Interact Cardiovasc Thorac Surg; 2010 Mar; 10(3):371-6. PubMed ID: 20026488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function.
    Butler J; Murithi EW; Pathi VL; MacArthur KJ; Berg GA
    Ann Thorac Surg; 2002 Jul; 74(1):139-42. PubMed ID: 12118746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of modified ultrafiltration in adults undergoing coronary artery bypass grafting is associated with inflammatory modulation and less postoperative blood loss: a randomized and controlled study.
    Torina AG; Silveira-Filho LM; Vilarinho KA; Eghtesady P; Oliveira PP; Sposito AC; Petrucci O
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):663-70. PubMed ID: 22578899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass.
    Wan S; DeSmet JM; Barvais L; Goldstein M; Vincent JL; LeClerc JL
    J Thorac Cardiovasc Surg; 1996 Sep; 112(3):806-11. PubMed ID: 8800171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Activation of endothelium in cardiac surgery: the circulating levels of soluble E-selectin as a marker of the activation of endothelium].
    Yamada H; Hirose Y; Toyoshima M; Kobayashi H; Kurahashi K; Kudoh I
    Masui; 1997 Apr; 46(4):478-83. PubMed ID: 9128018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
    Ovrum E; Am Holen E; Tangen G; Ringdal MA
    Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression changes in leukocytes during cardiopulmonary bypass are dependent on circuit coating.
    Seeburger J; Hoffmann J; Wendel HP; Ziemer G; Aebert H
    Circulation; 2005 Aug; 112(9 Suppl):I224-8. PubMed ID: 16159821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit.
    Francalancia NA; Aeba R; Yousem SA; Griffith BP; Marrone GC
    J Heart Lung Transplant; 1994; 13(3):498-507. PubMed ID: 8061027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.